Codis to acquire Catalent’s Nottingham site, targeting Q3 2026 close

The deal adds small-scale oral solid dose development and manufacturing in the UK and complements Codis’ planned GEA Pharma-SD PSD-4 spray-drying expansion in Haverhill.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.